- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06337032
Une étude visant à fournir un accès continu au médicament à l'étude aux enfants et adolescents ayant terminé des études cliniques impliquant les traitements Gilead contre le VIH
Une étude ouverte à un seul groupe visant à fournir un accès continu au médicament à l'étude aux participants qui ont terminé des études cliniques pédiatriques impliquant les traitements Gilead contre le VIH
The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.
The primary objectives of this study are as follows:
- To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment.
- To evaluate the safety of the study drug(s) in participants with HIV-1.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: F/TAF (High Dose Tablet)
- Médicament: F/TAF (Low Dose Tablet)
- Médicament: F/TAF (Lowest Dose Tablet)
- Médicament: B/F/TAF (High Dose)
- Médicament: B/F/TAF (Low Dose)
- Médicament: B/F/TAF (High Dose TOS)
- Médicament: 3rd ARV Agent
- Médicament: E/C/F/TAF
- Médicament: E/C/F/TAF (Low Dose)
- Médicament: F/TAF (High Dose TOS)
- Médicament: F/TAF (Low Dose TOS)
- Médicament: F/TAF (Lowest Dose TOS)
- Médicament: Cobicistat (High Dose)
- Médicament: Cobicistat (Low Dose)
- Médicament: Cobicistat (TOS)
- Médicament: B/F/TAF (Low Dose TOS)
- Médicament: B/F/TAF (Lowest Dose TOS)
- Médicament: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
- Médicament: ATV
- Médicament: DRV
- Médicament: Lopinavir Boosted with ritonavir (LPV/r)
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Gilead Clinical Study Information Center
- Numéro de téléphone: 1-833-445-3230 (GILEAD-0)
- E-mail: GileadClinicalTrials@gilead.com
Lieux d'étude
-
-
-
Cape Town, Afrique du Sud, 7505
- Recrutement
- University of Stellenbosch
-
Durban, Afrique du Sud, 3629
- Recrutement
- Enhancing Care Foundation
-
Johannesburg, Afrique du Sud, 2112
- Recrutement
- Rahima Moosa Mother and Child Hospital
-
Johannesburg, Afrique du Sud, 2038
- Recrutement
- WITS RHI Research Centre
-
Paarl, Afrique du Sud, 7626
- Recrutement
- Be Part Yoluntu Centre
-
Pretoria, Afrique du Sud, 0087
- Recrutement
- The Aurun Institute
-
Soweto, Afrique du Sud, 2013
- Recrutement
- Perinatal HIV Research Unit
-
-
-
-
-
Buenos Aires, Argentine, C1141 ACG
- Complété
- Helios Salud
-
-
-
-
-
Kampala, Ouganda, 10005
- Recrutement
- Joint Clinical Research Centre
-
Kampala, Ouganda, 256
- Recrutement
- MU-JHU Research Collaboration/MU-JHU Care Ltd
-
Kampala, Ouganda
- Recrutement
- Baylor College of Medicine
-
Kampala, Ouganda
- Recrutement
- Strengthening Institutional Capacity for Research Administration (SICRA)
-
Masaka, Ouganda
- Recrutement
- Africa Medical and Behavioral Sciences Organisation
-
-
-
-
-
Panama City, Panama, 0816-00383
- Complété
- Hospital del Niño
-
-
-
-
-
Bangkok Noi, Thaïlande, 10700
- Actif, ne recrute pas
- Faculty of Medicine - Mahidol University
-
Khon Kaen, Thaïlande, 40002
- Actif, ne recrute pas
- Khon Kaen University
-
-
-
-
-
Harare, Zimbabwe
- Recrutement
- University of Zimbabwe Clinical Research Centre
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Completed an applicable parent study: GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, or GS-US-216-0128, and gave consent to study participation.
Key Exclusion Criteria:
-
Individuals planning to switch to B/F/TAF on Day 1 with plasma HIV RNA ≥ 50 copies/mL during the last parent study visit prior to screening/Day 1 visit.
- Note: individuals planning to switch after Day 1 must not have plasma HIV RNA ≥ 50 copies/mL (or detectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
-
Individuals planning to switch to B/F/TAF with any ongoing Grade 3 or 4 drug-related AE or clinically relevant Grade 3 or 4 drug-related laboratory abnormality (confirmed on repeat) related to any component of B/F/TAF prior to treatment switch.
-
For those on B/F/TAF or planning to switch to B/F/TAF: previous treatment discontinuation of any component of B/F/TAF due to toxicity or intolerance.
-
For those planning to switch to B/F/TAF: known hypersensitivity to any component of the study drug, its metabolites, or formulation excipients.
-
Ongoing treatment with or prior use of any prohibited medications.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Rollover from Parent Study: GS-US-311-1269: Parent Study Drug (F/TAF) or B/F/TAF
Participants will continue to take the study drug they were taking in the parent study, emtricitabine/tenofovir alafenamide (F/TAF) along with a 3rd antiretroviral (ARV) agent. The dose of F/TAF will be based on the weight of the participant, ranging between 120/15 mg to 200/25 mg. The dose of F/TAF will be different when given with the boosted and the unboosted 3rd ARV agent: F/TAF (High Dose Tablet) for unboosted 3rd ARV agent; F/TAF (Low Dose Tablet) for the boosted 3rd ARV agent. Participants may switch to B/F/TAF, at a dose based on participant's weight. |
200/25 mg fixed-dose combination (FDC) tablet administered orally
Autres noms:
200/10 mg FDC tablet administered orally 120/15 mg FDC tablet administered orally 50/200/25 mg FDC tablet administered orally
Autres noms:
30/120/15 mg FDC tablet administered orally
Autres noms:
15/60/7.52 mg TOS administered orally
Autres noms:
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country |
|
Expérimental: Rollover from Parent Study: GS-US-292-0106: Parent Study Drug (E/C/F/TAF) or B/F/TAF
Participants will continue to take the study drug they were taking in the parent study, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF). The dose of E/C/F/TAF will be based on the weight of the participant, ranging between 90/90/120/6 mg to 150/150/200/10 mg. Participants may switch to B/F/TAF at a dose based on participant's weight. |
50/200/25 mg FDC tablet administered orally
Autres noms:
30/120/15 mg FDC tablet administered orally
Autres noms:
150/150/200/10 mg tablet administered orally
Autres noms:
90/90/120/6 mg tablet administered orally |
|
Expérimental: Rollover Parent Study GS-US-216-0128: Parent Study Drug (Combination Drugs) or B/F/TAF
Participants will continue to take the following study drugs they were taking in the parent study:
The dose of F/TAF will be based on the weight of the participant, ranging between 15/1.88 mg and 200/25 mg, once daily. Additionally, the dose of COBI will be based on the weight of the participant, ranging between 30 mg and 150 mg, once or twice daily. Participants may switch to B/F/TAF at a dose based on participant's weight. |
200/25 mg fixed-dose combination (FDC) tablet administered orally
Autres noms:
120/15 mg FDC tablet administered orally 50/200/25 mg FDC tablet administered orally
Autres noms:
30/120/15 mg FDC tablet administered orally
Autres noms:
15/60/7.52 mg TOS administered orally
Autres noms:
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country 60/7.5 mg tablet for oral suspension (TOS) administered orally 30/3.75 mg TOS administered orally 15/1.88 mg TOS administered orally 150 mg tablet administered orally
Autres noms:
90 mg tablet administered orally
Autres noms:
30 mg TOS administered orally
Autres noms:
7.5/30/3.76 mg TOS administered orally
Autres noms:
3.76/15/1.88 mg TOS administered orally
Autres noms:
NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC) Administered according to the prescribing information Administered according to the prescribing information Administered according to the prescribing information |
|
Expérimental: Rollover from Parent Studies: GS-US-380-1474 and CO-US-380-5578: Parent Study Drug (B/F/TAF)
Participants will continue to take the study drug they were taking in the parent study, B/F/TAF. Participants who are diagnosed with HIV-1 infection in parent study CO-US-380-5578 and complete the study drug will continue to take the study drug they were taking in the parent study, B/F/TAF. The dose of B/F/TAF will be based on the weight of the participant. |
50/200/25 mg FDC tablet administered orally
Autres noms:
30/120/15 mg FDC tablet administered orally
Autres noms:
15/60/7.52 mg TOS administered orally
Autres noms:
7.5/30/3.76 mg TOS administered orally
Autres noms:
3.76/15/1.88 mg TOS administered orally
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the Study
Délai: Up to 2.8 Years
|
Up to 2.8 Years
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Pourcentage de participants ayant subi des événements indésirables survenus pendant le traitement (TEAE)
Délai: Jusqu'à 9,5 ans
|
Jusqu'à 9,5 ans
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Gilead Study Director, Gilead Sciences
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Préparations pharmaceutiques
- Formulaires de dosage
- Thiazoles
- Azoles
- Acides nucléiques, nucléotides et nucléosides
- Acides, acyclique
- Acides carboxyliques
- Purines
- Désoxycytidine
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Composés organophosphores
- Nucléosides
- Désoxyribonucléosides
- Organophosphonate
- Adénine
- Combinaisons de médicaments
- Ténofovir
- Emtricitabine
- Carbamates
- Cobicistat
- Elvitégravir, cobicistat, emtricitabine, combinaison médicamenteuse de fumarate de ténofovir disoproxil
- Ritonavir
- Comprimés
- biicgravir, emtricitabine, ténofovir alafénamide, combinaison de médicaments
- Emtricitabine Tenofovir Arénamide
Autres numéros d'identification d'étude
- GS-US-380-6684
- 2024-000521-40 (Autre identifiant: European Medicines Agency)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .